Pet longevity biotech boasts stem cell therapies for dogs and cats, targeting osteoarthritis, atopic dermatitis and chronic kidney disease.
Animal health biotech Gallant has secured $18 million in Series B financing to support the advancement and commercialization of its “off-the-shelf” stem cell therapies for pets. The San Diego-based company says the investment will enable it to accelerate the path to conditional FDA approval of its lead therapy and expand its pipeline of regenerative treatments for cats and dogs.
Gallant is developing stem cell-based therapies that address the underlying causes of some of the most common and poorly managed chronic conditions in companion animals. The company is advancing a portfolio of off-the-shelf stem cell treatments aimed at other widespread conditions in dogs and cats, including osteoarthritis, atopic dermatitis and chronic kidney disease. These therapies are being developed to go beyond symptomatic relief, aiming instead to intervene at the root of disease pathology.
Gallant’s lead candidate targets feline chronic gingivostomatitis (FCGS), a painful and often treatment-resistant inflammatory condition in cats. The therapy, based on allogeneic uterine-derived mesenchymal stem cells, is expected to receive conditional FDA approval in early 2026. If approved, it will mark the first FDA-labeled allogeneic stem cell therapy in veterinary medicine.
Gallant’s proprietary platform uses stem cells derived from uterine tissue, chosen for their regenerative properties and scalability. By offering off-the-shelf formulations, the company says its approach eliminates the need for individualized cell harvesting, making its treatments more practical for widespread clinical use.
The latest funding round, which builds on last year’s $15 million Series A, was again led by Digitalis Ventures and includes continued backing from BOLD Capital and Hill Creek Partners, as well as new participation from NovaQuest Capital Management, an investor with direct experience in human stem cell therapy development.
“Regenerative medicine is entering its prime – we’ve seen it firsthand with the success of allogeneic stem cell therapies in human healthcare,” said Brian Axe, Partner at NovaQuest. “Gallant is bringing that same caliber of science to animal health with off-the-shelf therapies for pets targeting the root cause of disease where current care falls short.”
Photograph: katrinasid/Envato
The post Gallant fetches $18m to advance regenerative medicine for pets appeared first on Longevity.Technology – Latest News, Opinions, Analysis and Research.
